Abstract
Hairy cell leukemia is a rare, indolent, chronic lymphoproliferative disorder characterized by the proliferation of a malignant B-cell clone with irregular cytoplasmic projections. Treatment with purine analogs such as 2-chlorodeoxyadenosine (2-CdA) is associated with excellent remission rates and long-term survival. Although the majority of patients achieve a complete remission (CR), most have minimal residual disease detected by sensitive methods. Despite the long term disease-free survival, approximately 36% of patients relapse and many require further therapy. Repeat administration of 2-CdA is very effective in achieving a second CR. Recently, new agents such rituximab and BL22 were shown to be effective in the treatment of relapsed and refractory disease.
Original language | English (US) |
---|---|
Pages (from-to) | 2301-2307 |
Number of pages | 7 |
Journal | Leukemia and Lymphoma |
Volume | 47 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2006 |
Externally published | Yes |
Keywords
- 2-CdA
- Hairy cell leukemia
- Purine analogs
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research